Deferiprone versus desferrioxamine in thalassaemia, and T2* validation and utility.
St Pierre
T G
TG
D000284:Administration, Oral; D000077543:Deferiprone; D003676:Deferoxamine / Q000008:administration & dosage / Q000627:therapeutic use*; D006321:Heart / Q000187:drug effects; D006801:Humans; D007279:Injections, Subcutaneous; D007502:Iron Chelating Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D016014:Linear Models; D008099:Liver / Q000187:drug effects* / Q000378:metabolism; D011728:Pyridones / Q000008:administration & dosage / Q000627:therapeutic use*; D017086:beta-Thalassemia / Q000188:drug therapy*
D007502:Iron Chelating Agents; D011728:Pyridones; D000077543:Deferiprone; D003676:Deferoxamine